.....Our previously communicated intention to use the MBA resulted from Neuren’s proposal and was not a directive from the FDA.
Anyone who still thinks the results are poor and won't allow progression to phase 3 are kidding themselves. As above the FDA did not direct neu to use the MBA as the p3 end point it was based on neu's less informed decision at the time. The 2b trial has given them much more information and the end points will be modified accordingly
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.85 |
Change
-0.110(0.85%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.53 | $6.559M | 511.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1657 | $12.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.85 | 6303 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |